David Capper

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8112466/publications.pdf

Version: 2024-02-01

268 papers	30,590 citations	5268 83 h-index	5394 164 g-index
279 all docs	279 docs citations	279 times ranked	27814 citing authors

#	Article	IF	Citations
1	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. Seminars in Cancer Biology, 2022, 84, 129-143.	9.6	41
2	Mucosal melanomas of different anatomic sites share a common global <scp>DNA</scp> methylation profile with cutaneous melanoma but show locationâ€dependent patterns of genetic and epigenetic alterations. Journal of Pathology, 2022, 256, 61-70.	4.5	12
3	Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathology Research and Practice, 2022, 229, 153689.	2.3	1
4	Machine learning models predict the primary sites of head and neck squamous cell carcinoma metastases based on <scp>DNA</scp> methylation. Journal of Pathology, 2022, 256, 378-387.	4.5	19
5	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	5.2	12
6	Lowâ€grade diffusely infiltrative tumour (LGDIT), SMARCB1â€mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRTâ€MYC. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	5
7	A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. Nature Methods, 2022, 19, 296-306.	19.0	46
8	DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Medicine, 2022, 14, 24.	8.2	12
9	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	1.2	11
10	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	7.7	18
11	DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas. Lung Cancer, 2022, 170, 105-113.	2.0	3
12	Management of pineal region tumors in a pediatric case series. Neurosurgical Review, 2021, 44, 1417-1427.	2.4	25
13	Accurate calling of KIAA1549â€BRAF fusions from DNA of human brain tumours using methylation arrayâ€based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	3.2	12
14	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro-Oncology, 2021, 23, 240-250.	1.2	31
15	TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. Acta Neuropathologica, 2021, 141, 959-970.	7.7	16
16	High-grade astrocytoma with piloid features (HGAP): the CharitÃ© experience with a new central nervous system tumor entity. Journal of Neuro-Oncology, 2021, 153, 109-120.	2.9	35
17	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
18	Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippelâ€“Lindau diseaseâ€related tumours. Neuropathology and Applied Neurobiology, 2021, 47, 756-767.	3.2	2

#	Article	IF	Citations
19	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
20	IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies. American Journal of Surgical Pathology, 2021, 45, 1190-1204.	3.7	26
21	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33
22	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
23	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	7.7	16
24	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. Acta Neuropathologica, 2021, 142, 873-886.	7.7	12
25	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
26	Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy. Neuro-Oncology Advances, 2021, 3, vdab149.	0.7	23
27	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	7.7	7
28	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics, 2021, 13, 184.	4.1	2
29	FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. Neuro-Oncology Practice, 2021, 8, 209-221.	1.6	7
30	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	7.7	83
31	Reflection of neuroblastoma intratumor heterogeneity in the new OHCâ€NB1 disease model. International Journal of Cancer, 2020, 146, 1031-1041.	5.1	9
32	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. Nature Protocols, 2020, 15, 479-512.	12.0	89
33	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. The Lancet Child and Adolescent Health, 2020, 4, 121-130.	5.6	55
34	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. Pathology Research and Practice, 2020, 216, 152728.	2.3	8
35	Response to trametinib treatment in progressive pediatric low-grade glioma patients. Journal of Neuro-Oncology, 2020, 149, 499-510.	2.9	68
36	Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathologica, 2020, 140, 569-581.	7.7	45

#	Article	IF	Citations
37	Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. Acta Neuropathologica, 2020, 140, 893-906.	7.7	19
38	Malignant transformation and genetic alterations are uncoupled in early colorectal cancer progression. BMC Biology, 2020, 18, 116.	3.8	16
39	Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model. BMC Cancer, 2020, 20, 427.	2.6	3
40	An 8â€Yearâ€Old Girl with Posterior Fossa Mass. Brain Pathology, 2020, 30, 713-714.	4.1	1
41	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	4.1	168
42	Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas. Acta Neuropathologica, 2020, 140, 95-97.	7.7	7
43	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Investigational New Drugs, 2020, 38, 1570-1579.	2.6	70
44	Invited Review: DNA methylationâ€based classification of paediatric brain tumours. Neuropathology and Applied Neurobiology, 2020, 46, 28-47.	3.2	33
45	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
46	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
47	Review: Challenges in the histopathological classification of ganglioglioma and DNT: microscopic agreement studies and a preliminary genotypeâ€phenotype analysis. Neuropathology and Applied Neurobiology, 2019, 45, 95-107.	3.2	46
48	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical Epigenetics, 2019, 11, 117.	4.1	21
49	New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X. Scientific Reports, 2019, 9, 9973.	3.3	6
50	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers, 2019, 11, 1072.	3.7	16
51	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
52	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nature Communications, 2019, 10, 3914.	12.8	65
53	Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. Science Translational Medicine, 2019, 11, .	12.4	100
54	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. Cancers, 2019, 11, 122.	3.7	25

#	Article	IF	Citations
55	DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. Modern Pathology, 2019, 32, 855-865.	5.5	36
56	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica, 2019, 138, 497-504.	7.7	57
57	Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. Acta Neuropathologica, 2019, 138, 331-334.	7.7	22
58	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathologica Communications, 2019, 7, 24.	5.2	101
59	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathologica, 2019, 137, 837-846.	7.7	43
60	RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMA. Neuro-Oncology, 2019, 21, vi219-vi220.	1.2	1
61	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Childrenâ€™s Oncology Group ACNS0332 Trial. American Journal of Neuroradiology, 2019, 40, 1796-1803.	2.4	11
62	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
63	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
64	Integrated molecular characterization of <scp>IDH</scp>â€mutant glioblastomas. Neuropathology and Applied Neurobiology, 2019, 45, 108-118.	3.2	68
65	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	7.0	55
66	Multicentric malignant glioma with striking morphologic heterogeneity and early and extensive metastatic spread to the bone. , 2019, 38, 261-268.		0
67	The miRâ€139â€5p regulates proliferation of supratentorial paediatric lowâ€grade gliomas by targeting the PI3K/AKT/mTORC1 signalling. Neuropathology and Applied Neurobiology, 2018, 44, 687-706.	3.2	31
68	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	7.7	281
69	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
70	Preoperative assessment of haemostasis in patients undergoing stereotactic brain biopsy. Journal of Clinical Neuroscience, 2018, 53, 112-116.	1.5	13
71	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Annals of Oncology, 2018, 29, 1423-1430.	1.2	65
72	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	7.7	145

#	Article	IF	Citations
73	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationâ€"the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	1.2	32
74	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. American Journal of Surgical Pathology, 2018, 42, 506-511.	3.7	43
75	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
76	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
77	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
78	CASP9 germline mutation in a family with multiple brain tumors. Brain Pathology, 2018, 28, 94-102.	4.1	11
79	Glial papillary tumour of the spinal cord with <scp>SMARCB</scp>1/<scp>INI</scp>1â€loss and favourable longâ€term outcome. Neuropathology and Applied Neurobiology, 2018, 44, 229-232.	3.2	3
80	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. Neuro-Oncology, 2018, 20, 848-857.	1.2	170
81	The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. Journal of Clinical Neuroscience, 2018, 47, 163-167.	1.5	8
82	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathology, 2018, 28, 656-662.	4.1	89
83	<scp>WHO</scp> 2016 Classification of gliomas. Neuropathology and Applied Neurobiology, 2018, 44, 139-150.	3.2	612
84	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Childrenâ€™s Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology, 2018, 36, 3388-3395.	1.6	58
85	Modern Principles of CNS Tumor Classification. , 2018, , 117-129.		0
86	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	7.7	195
87	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP ACNS0332 TRIAL. Neuro-Oncology, 2018, 20, i68-i69.	1.2	0
88	Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics. Neuro-Oncology, 2018, 20, 1682-1683.	1.2	8
89	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
90	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell, 2018, 33, 829-842.e5.	16.8	140

#	Article	IF	Citations
91	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	7.7	308
92	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro-Oncology, 2018, 20, 1616-1624.	1.2	65
93	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. Neuro-Oncology, 2018, 20, i144-i145.	1.2	1
94	Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. Frontiers in Neurology, 2018, 9, 398.	2.4	10
95	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. Molecular Cancer Research, 2018, 16, 1491-1498.	3.4	39
96	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nature Communications, 2018, 9, 2868.	12.8	54
97	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. Neuro-Oncology, 2018, 20, 1517-1524.	1.2	36
98	Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma. Oncotarget, 2018, 9, 24041-24053.	1.8	8
99	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	7.7	146
100	A 49â€year old female with multiple extraâ€axial tumors. Brain Pathology, 2017, 27, 235-236.	4.1	0
101	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathologica, 2017, 134, 507-516.	7.7	144
102	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	10.7	586
103	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	7.7	12
104	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
105	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Molecular Therapy, 2017, 25, 2620-2634.	8.2	199
106	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
107	Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. Journal of Neuropathology and Experimental Neurology, 2017, 76, 655-664.	1.7	13
108	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clinical Sarcoma Research, 2017, 7, 9.	2.3	51

#	Article	IF	Citations
109	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathologica, 2017, 133, 417-429.	7.7	172
110	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 27, 851-852.	4.1	63
111	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1â€deficient nonâ€rhabdoid tumor with favorable longâ€term outcome. Brain Pathology, 2017, 27, 411-418.	4.1	58
112	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences, 2017, 18, 995.	4.1	32
113	Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. Oncotarget, 2017, 8, 67567-67591.	1.8	11
114	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	1.8	43
115	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncology Reports, 2017, 38, 3291-3296.	2.6	46
116	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	4.1	14
117	LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wildâ€type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432.	5.1	18
118	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathology, 2016, 26, 199-205.	4.1	39
119	Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427.	2.8	34
120	Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. Brain Pathology, 2016, 26, 517-522.	4.1	63
121	Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Medicine, 2016, 14, 170.	5.5	31
122	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathologica, 2016, 132, 149-151.	7.7	127
123	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532.	10.7	396
124	HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2016, 18, iii63.2-iii63.	1.2	0
125	Next-generation personalised medicine for high-risk paediatric cancer patients â€“ The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
126	SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. Child's Nervous System, 2016, 32, 2439-2446.	1.1	15

#	Article	IF	Citations
127	Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathologica, 2016, 132, 635-637.	7.7	73
128	Radiogenomics of Glioblastoma: Machine Learningâ€“based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology, 2016, 281, 907-918.	7.3	236
129	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nature Medicine, 2016, 22, 1314-1320.	30.7	183
130	Low-grade epilepsy-associated neuroepithelial tumours â€" the 2016 WHO classification. Nature Reviews Neurology, 2016, 12, 732-740.	10.1	113
131	P08.48â€,Combined alterations in MAPK pathway genes, CDKN2A/B and ATRX characterize anaplastic pilocytic astrocytoma. Neuro-Oncology, 2016, 18, iv52-iv52.	1.2	0
132	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naÃ¯ve patients. BMC Cancer, 2016, 16, 81.	2.6	51
133	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathologica Communications, 2016, 4, 20.	5.2	136
134	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. Journal of Neuro-Oncology, 2016, 129, 319-328.	2.9	25
135	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
136	Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis. Journal of Neuropathology and Experimental Neurology, 2016, 75, 358-365.	1.7	27
137	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathologica, 2016, 131, 877-887.	7.7	151
138	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro-Oncology, 2016, 18, 790-796.	1.2	67
139	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
140	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
141	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1146-1156.	1.2	197
142	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	6.3	283
143	Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathologica, 2016, 131, 309-319.	7.7	74
144	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146.	7.7	162

#	Article	IF	Citations
145	Synchronous pituitary adenoma and pituicytoma. Human Pathology, 2016, 47, 138-143.	2.0	18
146	Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 382-388.	1.2	7
147	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544.	1.2	38
148	Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget, 2015, 6, 13579-13590.	1.8	21
149	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
150	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	7.7	74
151	Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children. Acta Neuropathologica, 2015, 129, 925-927.	7.7	35
152	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	7.7	272
153	Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1131-1137.	2.5	30
154	BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum. Journal of Neuropathology and Experimental Neurology, 2015, 74, 867-872.	1.7	51
155	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. Brain Pathology, 2015, 25, 202-208.	4.1	66
156	<scp>BRAF V</scp>600<scp>E</scp> analysis for the differentiation of papillary craniopharyngiomas and <scp>R</scp>athke's cleft cysts. Neuropathology and Applied Neurobiology, 2015, 41, 733-742.	3.2	50
157	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	7.7	277
158	Intramedullary Solitary Fibrous Tumorâ€"A Benign Form of Hemangiopericytoma? Case Report and Review of the Literature. World Neurosurgery, 2015, 84, 189.e7-189.e12.	1.3	10
159	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	7.7	237
160	Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocrine-Related Cancer, 2015, 22, 419-429.	3.1	68
161	Risk factors for glioblastoma therapy associated complications. Clinical Neurology and Neurosurgery, 2015, 134, 55-59.	1.4	21
162	Tumour necrosis factor receptor superfamily member 9 (<scp>TNFRSF</scp>9) is upâ€regulated in reactive astrocytes in human gliomas. Neuropathology and Applied Neurobiology, 2015, 41, e56-67.	3.2	7

#	Article	IF	Citations
163	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an â€œintegratedâ€•diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	7.7	378
164	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. Journal of Clinical Investigation, 2015, 125, 593-606.	8.2	35
165	The evolution of the anaplastic cerebellar liponeurocytoma: case report and review of the literature. , 2015, 34, 19-25.		15
166	Survival According to BRAF-V600 Tumor Mutations â€“ An Analysis of 437 Patients with Primary Melanoma. PLoS ONE, 2014, 9, e86194.	2.5	42
167	Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 661-672.	2.8	61
168	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Modern Pathology, 2014, 27, 1028-1034.	5.5	96
169	Detection ofBRAFp.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	2.5	57
170	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	1.2	77
171	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-Oncology, 2014, 16, 92-102.	1.2	57
172	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Archives of Dermatological Research, 2014, 306, 873-884.	1.9	11
173	The embryonic stem cell factor UTF1 serves as a reliable diagnostic marker for germinomas. Pathology, 2014, 46, 225-229.	0.6	8
174	Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy. American Journal of Emergency Medicine, 2014, 32, 947.e3-947.e5.	1.6	17
175	Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathologica, 2014, 127, 565-572.	7.7	41
176	<scp>BRAF V600E</scp> Mutation Is Associated with <scp>mTOR</scp> Signaling Activation in Glioneuronal Tumors. Brain Pathology, 2014, 24, 52-66.	4.1	129
177	Diagnostic Value of Immunohistochemistry for the Detection of the BRAF^{V600E} Mutation in Papillary Thyroid Carcinoma: Comparative Analysis with Three DNA-Based Assays. Thyroid, 2014, 24, 858-866.	4.5	57
178	Nuclear relocation of <scp>STAT</scp>6 reliably predicts NAB2â€“STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology, 2014, 65, 613-622.	2.9	101
179	Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro-Oncology, 2014, 16, 914-923.	1.2	69
180	<scp>BRAF</scp>â€Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <scp>CD</scp>34 Expression. Brain Pathology, 2014, 24, 221-229.	4.1	72

#	Article	IF	Citations
181	Loss of FUBP1 expression in gliomas predictsFUBP1mutation and is associated with oligodendroglial differentiation,IDH1mutation and 1p/19q loss of heterozygosity. Neuropathology and Applied Neurobiology, 2014, 40, 205-216.	3.2	41
182	GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.9	54
183	NEXT-GENERATION NEUROPATHOLOGY - IMPROVING DIAGNOSTIC ACCURACY FOR BRAIN TUMORS USING DNA METHYLATION ARRAY-BASED MOLECULAR PROFILING. Neuro-Oncology, 2014, 16, iii4-iii4.	1.2	4
184	Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Modern Pathology, 2014, 27, 135-144.	5.5	49
185	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. Journal of Clinical Neuroscience, 2014, 21, 1945-1950.	1.5	8
186	p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. Cell, 2014, 158, 579-592.	28.9	176
187	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. Journal of Neurochemistry, 2014, 131, 251-264.	3.9	47
188	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	7.7	176
189	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathologica, 2014, 128, 551-559.	7.7	268
190	SPONTANEOUS IMMUNE RESPONSES IN GBM PATIENTS AFTER COMPLETE TUMOR RESECTION ARE ASSOCIATED WITH AN IMPROVED SURVIVAL. Neuro-Oncology, 2014, 16, iii42-iii42.	1.2	2
191	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	7.7	304
192	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900.	7.7	177
193	VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathologica, 2013, 125, 911-912.	7.7	28
194	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathologica, 2013, 125, 651-658.	7.7	324
195	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathologica, 2013, 125, 351-358.	7.7	208
196	BRAF V600Eâ€specific immunohistochemistry for the exclusion of Lynch syndrome in MSIâ€H colorectal cancer. International Journal of Cancer, 2013, 133, 1624-1630.	5.1	93
197	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	7.7	254
198	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathologica, 2013, 126, 757-762.	7.7	88

#	Article	IF	Citations
199	Antiâ€tissue factor (<scp>TF9â€10H10</scp>) treatment reduces tumor cell invasiveness in a novel migratory glioma model. Neuropathology, 2013, 33, 515-525.	1.2	13
200	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, 2013, 26, 1255-1263.	5.5	52
201	Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients. Annals of Oncology, 2013, 24, 742-748.	1.2	103
202	A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biology, 2013, 15, 978-990.	10.3	1,566
203	Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Human Pathology, 2013, 44, 329-335.	2.0	77
204	Detection of BRAF p.V600E Mutations in Melanomas. Journal of Molecular Diagnostics, 2013, 15, 94-100.	2.8	144
205	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 2013, 15, 1017-1026.	1.2	78
206	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1416-1425.	4.9	62
207	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. British Journal of Cancer, 2013, 108, 924-931.	6.4	55
208	No Evidence for BRAF-V600E Mutations in Gastroeosophageal Tumors. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 426-430.	1.2	12
209	Differential Expression of the Tumor Suppressor A-Kinase Anchor Protein 12 in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. Journal of Neuropathology and Experimental Neurology, 2013, 72, 933-941.	1.7	11
210	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. American Journal of Surgical Pathology, 2013, 37, 1592-1602.	3.7	125
211	Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 159-164.	1.2	27
212	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 351-353.	1.2	7
213	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma. Clinical Cancer Research, 2013, 19, 6716-6729.	7.0	50
214	Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discovery, 2013, 3, 862-869.	9.4	202
215	Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. Journal of Clinical Oncology, 2013, 31, e300-e303.	1.6	67
216	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology, 2013, 37, 61-65.	3.7	289

#	Article	IF	Citations
217	Chromogenic in situ Hybridization is a Reliable Alternative to Fluorescence in situ Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffinâ€Embedded Gliomas. Brain Pathology, 2013, 23, 311-318.	4.1	21
218	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	7.8	110
219	Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis. Archives of Neurology, 2012, 69, 523.	4.5	148
220	Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia. American Journal of Surgical Pathology, 2012, 36, 1796-1800.	3.7	135
221	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2012, 36, 844-850.	3.7	177
222	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood, 2012, 120, e28-e34.	1.4	199
223	Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, 779-784.	3.1	65
224	Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. Journal of the American Academy of Dermatology, 2012, 67, 488-491.	1.2	51
225	2â€Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. International Journal of Cancer, 2012, 131, 766-768.	5.1	74
226	No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. Journal of Neuro-Oncology, 2012, 109, 15-22.	2.9	66
227	Detection of 2â€Hydroxyglutarate in Formalinâ€Fixed Paraffinâ€Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. Brain Pathology, 2012, 22, 26-31.	4.1	49
228	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica, 2012, 123, 223-233.	7.7	204
229	Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica, 2012, 123, 205-222.	7.7	163
230	Mutation specific antibodies: tool or dinosaur?. Oncotarget, 2012, 3, 907-908.	1.8	6
231	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
232	Diffuse Astrocytomas: Immunohistochemistry of MGMT Expression. , 2012, , 89-94.		0
233	Sensitivity of refractory hairy cell leukemia to BRAF inhibition.. Journal of Clinical Oncology, 2012, 30, 6519-6519.	1.6	0
234	Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. Blood, 2012, 120, 4600-4600.	1.4	0

#	Article	IF	Citations
235	BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. Blood, 2012, 120, 4040-4040.	1.4	1
236	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology, 2011, 58, 1167-1172.	2.9	13
237	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica, 2011, 121, 241-252.	7.7	124
238	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 397-405.	7.7	914
239	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathologica, 2011, 122, 11-19.	7.7	445
240	Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. Acta Neuropathologica, 2011, 122, 651-652.	7.7	13
241	IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, 30, 217-230.		55
242	Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes. American Journal of Surgical Pathology, 2010, 34, 1199-1204.	3.7	108
243	IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica, 2010, 95, 1797-1798.	3.5	13
244	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 2010, 120, 707-718.	7.7	719
245	Increased levels of 2â€hydroxyglutarate in AML patients with IDH1â€R132H and IDH2â€R140Q mutations. European Journal of Haematology, 2010, 85, 457-459.	2.2	39
246	Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leukemia Research, 2010, 34, 1091-1093.	0.8	18
247	Secreted protein, acidic and rich in cysteine (SPARC) expression in astrocytic tumour cells negatively correlates with proliferation, while vascular SPARC expression is associated with patient survival. Neuropathology and Applied Neurobiology, 2010, 36, 183-197.	3.2	16
248	PCRâ€•and Restriction Endonucleaseâ€Based Detection of IDH1 Mutations. Brain Pathology, 2010, 20, 298-300.	4.1	58
249	Characterization of R132H Mutationâ€specific IDH1 Antibody Binding in Brain Tumors. Brain Pathology, 2010, 20, 245-254.	4.1	463
250	Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology, 2010, 12, 894-907.	1.2	14
251	Modulation of TGFâ€Î² activity by latent TGFâ€Î²â€binding protein 1 in human malignant glioma cells. International Journal of Cancer, 2009, 125, 530-540.	5.1	53
252	Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathologica, 2009, 117, 445-456.	7.7	88

#	Article	IF	Citations
253	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathologica, 2009, 118, 401-405.	7.7	255
254	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 2009, 118, 469-474.	7.7	1,020
255	Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathologica, 2009, 118, 599-601.	7.7	380
256	Diagnostic value of WT1 in neuroepithelial tumours. Neuropathology and Applied Neurobiology, 2009, 35, 69-81.	3.2	24
257	EGRâ€1 is Regulated by Nâ€Methylâ€Dâ€Aspartateâ€Receptor Stimulation and Associated with Patient Survival in Human High Grade Astrocytomas. Brain Pathology, 2009, 19, 195-204.	4.1	24
258	Rathkeâ€™s cleft cyst rupture as potential initial event of a secondary perifocal lymphocytic hypophysitis: proposal of an unusual pathogenetic event and review of the literature. Neurosurgical Review, 2008, 31, 157-163.	2.4	31
259	Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathologica, 2008, 115, 249-259.	7.7	68
260	Primary anaplastic ganglioglioma with a small-cell glioblastoma component. , 2008, 27, 91-95.		15
261	Atypical Type II Silent Corticotrophic Adenoma Developing into Cushing's Disease upon Second Recurrence. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 610-615.	1.2	18
262	Expression pattern of the water channel aquaporin-4 in human gliomas is associated with bloodâ€“brain barrier disturbance but not with patient survival. Journal of Neuroscience Research, 2007, 85, 1336-1346.	2.9	120
263	De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathology and Applied Neurobiology, 2007, 33, 299-307.	3.2	18
264	Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. Journal of Neuroimmunology, 2007, 189, 50-58.	2.3	56
265	Multiple thromboembolic events in fetofetal transfusion syndrome in triplets contributing to the understanding of pathogenesis of hydranencephaly in combination with polymicrogyria. Human Pathology, 2006, 37, 1503-1507.	2.0	14
266	Differential microglial regulation in the human spinal cord under normal and pathological conditions. Neuropathology and Applied Neurobiology, 2006, 32, 650-661.	3.2	13
267	Coincidence of Semilobar Holoprosencephaly and Chiari II Malformation: Correlation of Prenatal Diagnostics and Neuropathologic Findings. Journal of Child Neurology, 2006, 21, 426-429.	1.4	5
268	Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy. Human Pathology, 2005, 36, 854-857.	2.0	12